breakout alert, page-3

The cost of trading ADR's and holding them would also provide enough insentive not to buy PSDV in the US.

The SP in the US hit another high @ $1.02 on the close levels which we have not seen for some 6 - 9 months !

Good news is brewing and I think that Paul has shown the market he has the ability to deliver the deals which can transfor this company.

Alimera are primed and ready to launch the product once FDA approval given and PSD's share could be substantial amounts of revenue (I believe could be $100 plus mil a year)